United States securities and exchange commission logo

                            April 29, 2021

       Marshall Fordyce, M.D.
       Chief Executive Officer and President
       Vera Therapeutics, Inc.
       170 Harbor Way, 3rd Floor
       South San Francisco, California 94080

                                                        Re: Vera Therapeutics,
Statement on Form S-1
                                                            Filed April 23,
                                                            File No. 333-255492

       Dear Dr. Fordyce:

                                                        We have reviewed your
registration statement and have the following comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1

       Phase 2 SLE Clinical Trial In Patients With SLE For 52 Weeks, page 112

   1.                                                   We note your revisions
in response to comment 1. Please also revise your disclosure that
                                                        "atacicept 150 mg
showed clinical efficacy," as efficacy determinations are solely within
                                                        the authority of the
FDA or similar foreign regulators. Relatedly, please revise the
                                                        subheading on page 114
entitled "Figure 20: Durable Efficacy Observed in HDA Patients
                                                        in the Phase 2 ADDRESS
II Trial."
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.
 Marshall Fordyce, M.D.
Vera Therapeutics, Inc.
April 29, 2021
Page 2

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

        You may contact Christie Wong at 202-551-3684 or Vanessa Robertson at
if you have questions regarding comments on the financial statements and
matters. Please contact Dillon Hagius at 202-551-7967 or Irene Paik at
202-551-6553 with any
other questions.

FirstName LastNameMarshall Fordyce, M.D.
                                                           Division of
Corporation Finance
Comapany NameVera Therapeutics, Inc.
                                                           Office of Life
April 29, 2021 Page 2
cc:       Jodie Bourdet
FirstName LastName